Skip to main content

Table 3 Glycemic control, markers of cardio-metabolic risk and oxidative stress at baseline and after the 8-week intervention in infertile polycystic ovary syndrome women candidate for in vitro fertilization that received either vitamin D supplements or placebo

From: The effects of vitamin D supplementation on metabolic profiles and gene expression of insulin and lipid metabolism in infertile polycystic ovary syndrome candidates for in vitro fertilization

  Placebo group (n = 20) Vitamin D group (n = 20) Pa
Baseline End-of-trial Change Baseline End-of-trial Change
Vitamin D (ng/mL) 11.0 ± 2.4 10.9 ± 2.1 -0.1 ± 0.6 10.5 ± 2.5 21.7 ± 5.9 11.2 ± 5.0 < 0.001
AMH (ng/mL) 8.7 ± 2.7 8.6 ± 2.5 -0.1 ± 0.5 7.7 ± 3.4 7.0 ± 3.1 −0.7 ± 1.2 0.02
FPG (mg/dL) 92.9 ± 5.5 93.5 ± 5.6 0.5 ± 3.0 90.3 ± 10.5 89.4 ± 10.6 −0.9 ± 7.4 0.42
Insulin (μIU/mL) 11.4 ± 1.9 11.1 ± 2.0 −0.3 ± 0.9 11.2 ± 2.2 9.8 ± 2.7 −1.4 ± 1.6 0.007
HOMA-IR 2.6 ± 0.5 2.5 ± 0.4 −0.1 ± 0.2 2.5 ± 0.7 2.2 ± 0.7 −0.3 ± 0.3 0.008
QUICKI 0.33 ± 0.008 0.33 ± 0.009 0.001 ± 0.004 0.33 ± 0.01 0.34 ± 0.02 0.009 ± 0.01 0.04
Triglycerides (mg/dL) 111.5 ± 35.5 117.4 ± 34.8 5.9 ± 13.2 105.3 ± 33.5 107.5 ± 38.1 2.1 ± 17.4 0.44
VLDL-cholesterol (mg/dL) 22.3 ± 7.1 23.5 ± 6.9 1.2 ± 2.6 21.1 ± 6.7 21.5 ± 7.6 0.4 ± 3.5 0.44
Total cholesterol (mg/dL) 197.1 ± 36.3 200.0 ± 36.5 2.9 ± 10.9 203.6 ± 26.6 198.5 ± 24.7 −5.1 ± 12.6 0.03
LDL-cholesterol (mg/dL) 124.9 ± 35.9 127.4 ± 35.3 2.5 ± 10.6 133.1 ± 21.1 128.7 ± 20.8 −4.5 ± 10.3 0.04
HDL-cholesterol (mg/dL) 49.9 ± 7.5 49.1 ± 8.2 −0.8 ± 3.9 49.4 ± 5.7 48.4 ± 5.4 −1.0 ± 2.8 0.81
  1. Data are means± SDs
  2. a Obtained from repeated measures ANOVA test
  3. AMH anti-Müllerian hormone, FPG fasting plasma glucose, HOMA-IR homeostasis model of assessment-estimated insulin resistance, QUICKI quantitative insulin sensitivity check index